The prognostic value of intraepithelial and stromal innate immune system cells in non-small cell lung carcinoma

Histopathology

Volumn 55, Issue 3, 2009, Pages 301-312

  Al Shibli, Khalid ^a,b   Al Saad, Samer ^b,c   Donnem, Tom ^b,c   Persson, Magnus ^b   Bremnes, Roy M ^b,c   Busund, Lill Tove ^b,c  

^a NORDLAND HOSPITAL   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

CSF 1R; Dendritic cells; M CSF; Macrophages; NK cells; NSCLC; Tumour stroma

Indexed keywords

CD56 ANTIGEN; CD68 ANTIGEN; COLONY STIMULATING FACTOR 1; COLONY STIMULATING FACTOR RECEPTOR; T6 ANTIGEN;

ADULT; AGED; ARTICLE; CORRELATION ANALYSIS; DENDRITIC CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROGNOSIS; STROMA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY;

AGED; ANTIGENS, CD; CARCINOMA, NON-SMALL-CELL LUNG; DENDRITIC CELLS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; HUMANS; KILLER CELLS, NATURAL; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGE COLONY-STIMULATING FACTOR; MACROPHAGES; MALE; NEOPLASM STAGING; NORWAY; PNEUMONECTOMY; PROGNOSIS; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; STROMAL CELLS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 69549112977     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2009.03379.x     Document Type: Article

References (46)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J. Clin. 2007 57 43 66.
2. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J. Clin. Oncol. 2004 22 3860 3867. (Pubitemid 41079866)
3. Salgaller ML. The development of immunotherapies for non-small cell lung cancer. Expert. Opin. Biol. Ther. 2002 2 265 278.
4. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 2006 6 24 37.
5. Lanier LL, Ruitenberg JJ, Phillips JH. Human CD3+ T lymphocytes that express neither CD4 nor CD8 antigens. J. Exp. Med. 1986 164 339 344.
6. Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J. Immunol. 1986 136 4480 4486.
7. Smyth MJ, Crowe NY, Hayakawa Y, Takeda K, Yagita H, Godfrey DI. NKT cells - conductors of tumor immunity? Curr. Opin. Immunol. 2002 14 165 171.
8. Ishigami S, Natsugoe S, Tokuda K et al. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 2000 88 577 583.
9. Coca S, Perez-Piqueras J, Martinez D et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 1997 79 2320 2328.
10. Wu J, Lanier LL. Natural killer cells and cancer. Adv. Cancer Res. 2003 90 127 156.
11. Hart DN. Dendritic cell biology evolves into clinical application. Lancet 2005 365 102 104.
12. La RG, Anzalone R, Bucchieri F, Farina F, Cappello F, Zummo G. CD1a and antitumour immune response. Immunol. Lett. 2004 95 1 4.
13. Cai XY, Gao Q, Qiu SJ et al. Dendritic cell infiltration and prognosis of human hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2006 132 293 301.
14. Coventry BJ, Morton J. CD1a-positive infiltrating-dendritic cell density and 5-year survival from human breast cancer. Br. J. Cancer 2003 89 533 538.
15. Inoshima N, Nakanishi Y, Minami T et al. The influence of dendritic cell infiltration and vascular endothelial growth factor expression on the prognosis of non-small cell lung cancer. Clin. Cancer Res. 2002 8 3480 3486.
16. Sandel MH, Dadabayev AR, Menon AG et al. Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin. Cancer Res. 2005 11 2576 2582.
17. Chang GC, Lan HC, Juang SH et al. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma. Cancer 2005 103 763 771.
18. Kataki A, Scheid P, Piet M et al. Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression. J. Lab. Clin. Med. 2002 140 320 328.
19. Tataroglu C, Kargi A, Ozkal S, Esrefoglu N, Akkoclu A. Association of macrophages, mast cells and eosinophil leukocytes with angiogenesis and tumor stage in non-small cell lung carcinomas (NSCLC). Lung Cancer 2004 43 47 54.
20. Welsh TJ, Green RH, Richardson D, Waller DA, O'Byrne KJ, Bradding P. Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J. Clin. Oncol. 2005 23 8959 8967.
21. Chitu V, Stanley ER. Colony-stimulating factor-1 in immunity and inflammation. Curr. Opin. Immunol. 2006 18 39 48.
22. Lin EY, Gouon-Evans V, Nguyen AV, Pollard JW. The macrophage growth factor CSF-1 in mammary gland development and tumor progression. J. Mammary Gland Biol. Neoplasia 2002 7 147 162.
23. Kaminska J, Kowalska M, Kotowicz B et al. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. Oncology 2006 70 115 125.
24. Sihoe AD, Yim AP. Lung cancer staging. J. Surg. Res. 2004 117 92 106.
25. World Health Organization. Tumours of the lung. In Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC eds. Tumours of the lung, pleura, thymus and heart. Lyon : International Agency for Research on Cancer, 2004 10.
26. Donnem T, Al-Saad S, Al-Shibli K et al. Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer. Clin. Cancer Res. 2007 13 6649 6657.
27. Wakabayashi O, Yamazaki K, Oizumi S et al. CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci. 2003 94 1003 1009.
28. Alavaikko MJ, Blanco G, Aine R et al. Follicular dendritic cells have prognostic relevance in Hodgkin's disease. Am. J. Clin. Pathol. 1994 101 761 767.
29. Schroder S, Schwarz W, Rehpenning W, Loning T, Bocker W. Dendritic/langerhans cells and prognosis in patients with papillary thyroid carcinomas. Immunocytochemical study of 106 thyroid neoplasms correlated to follow-up data. Am. J. Clin. Pathol. 1988 89 295 300.
30. Sprinzl GM, Hussl B, Obrist P et al. Dendritic cells in precancerous lesions of the larynx. Laryngoscope 2000 110 13 18.
31. Treilleux I, Blay JY, driss-Vermare N et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin. Cancer Res. 2004 10 7466 7474.
32. Gong X, Yan Y, Wu J. [Tumor infiltrating dendritic cells in relation to prognosis of lung cancer]. Zhonghua Zhong Liu Za Zhi 2000 22 135 137.
33. Zeid NA, Muller HK. S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival. Pathology 1993 25 338 343.
34. Kurabayashi A, Furihata M, Matsumoto M, Hayashi H, Ohtsuki Y. Distribution of tumor-infiltrating dendritic cells in human non-small cell lung carcinoma in relation to apoptosis. Pathol. Int. 2004 54 302 310.
35. Chan CW, Crafton E, Fan HN et al. Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat. Med. 2006 12 207 213.
36. Chan CW, Housseau F. The 'kiss of death' by dendritic cells to cancer cells. Cell Death Differ. 2008 15 58 69.
37. Zhong H, Han B, Tourkova IL et al. Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth. Clin. Cancer Res. 2007 13 5455 5462.
38. Krawczyk P, Wojas K, Milanowski J, Rolinski J. The influence of different culture microenvironment on the generation of dendritic cells from non-small-cell lung cancer patients. Arch. Immunol. Ther Exp. 2007 55 405 415.
39. Thorley AJ, Goldstraw P, Young A, Tetley TD. Primary human alveolar type II epithelial cell CCL20 (macrophage inflammatory protein-3alpha) induced dendritic cell migration. Am. J. Respir. Cell Mol. Biol. 2005 32 262 267.
40. Arenberg DA, Keane MP, DiGiovine B et al. Macrophage infiltration in human non-small-cell lung cancer: the role of CC chemokines. Cancer Immunol. Immunother. 2000 49 63 70.
41. Zins K, Abraham D, Sioud M, Aharinejad S. Colon cancer cell-derived tumor necrosis factor-alpha mediates the tumor growth-promoting response in macrophages by up-regulating the colony-stimulating factor-1 pathway. Cancer Res. 2007 67 1038 1045.
42. Pei XH, Nakanishi Y, Takayama K, Bai F, Hara N. Granulocyte, granulocyte-macrophage, and macrophage colony-stimulating factors can stimulate the invasive capacity of human lung cancer cells. Br. J. Cancer 1999 79 40 46.
43. Villegas FR, Coca S, Villarrubia VG et al. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 2002 35 23 28.
44. Takanami I, Takeuchi K, Giga M. The prognostic value of natural killer cell infiltration in resected pulmonary adenocarcinoma. J. Thorac. Cardiovasc. Surg. 2001 121 1058 1063.
45. Osada T, Clay T, Hobeika A, Lyerly HK, Morse MA. NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. Cancer Immunol. Immunother. 2006 55 1122 1131.
46. Klingemann H, Boissel L. Targeted cellular therapy with natural killer cells. Horm. Metab. Res. 2008 40 122 125.